Gilead Sciences Inc - GILD STOCK NEWS

Gilead Sciences has reaffirmed its commitment to combating the HIV epidemic by supporting the AIDS Memorial Quilt, the largest living memorial project with over 50,000 panels and 110,000 names of those lost to HIV-related causes.

The Quilt serves as both a tribute and an educational tool for HIV prevention. Gilead is displaying blocks of the Quilt at its Foster City campus and is creating a dedicated panel for those lost to HIV within the company.

Gilead has been a long-time supporter of initiatives aiming to end the HIV epidemic and continues to innovate in biopharmaceuticals with a global presence in over 35 countries.

Gilead Sciences emphasizes the ongoing efforts to address the disproportionate impact of HIV on Black communities during Black HIV/AIDS Awareness Day. The company acknowledges significant progress in education and access to screening, prevention, and care but highlights the need for continued work in these areas. As a research-based biopharmaceutical organization, Gilead aims to transform care for life-threatening illnesses globally, maintaining operations in over 35 countries with its headquarters in Foster City, California. Gilead's commitment remains strong in combating HIV/AIDS and promoting health equity.

Gilead Sciences (NASDAQ: GILD) announces positive Phase 1b trial results for lenacapavir in combination with two broadly neutralizing antibodies, teropavimab and zinlirvimab, as an investigational long-acting HIV treatment. The trial involved 20 virologically suppressed participants, 90% of whom maintained viral suppression at 26 weeks. The treatment was well tolerated with no serious adverse events reported. Moving forward, Gilead plans to initiate a Phase 2 study to further assess the safety and efficacy of this combination therapy later this year. These findings may enhance treatment options and adherence for people living with HIV.

Kite, a Gilead Company (NASDAQ: GILD), has completed its acquisition of Tmunity Therapeutics, a clinical-stage biotech firm focused on next-generation CAR T-cell therapies. This strategic move enhances Kite's pipeline and capabilities, adding pre-clinical and clinical programs, including an advanced 'armored' CAR T technology platform. Along with this acquisition, Kite also establishes a research and licensing agreement with the University of Pennsylvania, ensuring continued collaboration with Tmunity's founders, who will provide consulting services. The deal aims to bolster Kite’s position in cell therapy for cancer treatment.

Gilead Sciences (NASDAQ: GILD) announced promising outcomes from three real-world studies on Veklury (remdesivir) regarding COVID-19 treatment. Initiating Veklury within two days of hospitalization showed a significant reduction in mortality rates across various patient groups, including immunocompromised individuals. The studies involving over 800 U.S. hospitals revealed a 19% to 26% lower risk of mortality at Day 28. Additionally, Veklury-treated patients experienced a 27% reduction in hospital readmissions within 30 days. The in vitro studies confirmed Veklury's effectiveness against recent Omicron subvariants, indicating its continuing relevance in evolving pandemic conditions.

Gilead Sciences (NASDAQ: GILD) presented new findings at CROI 2023 highlighting innovative approaches in HIV research. These include targeting the HIV viral reservoir and enhancing immune response without antiretroviral therapy (ART). Key results from four studies were discussed, showcasing promising strategies such as dual treatment with broadly neutralizing antibodies (bNAbs), which delayed viral rebound. Gilead emphasizes the importance of collaboration in advancing HIV cure research and commits to exploring various combination strategies. The company aims to contribute significantly to the fight against the HIV epidemic.

Gilead Sciences has announced that the Mary Bird Perkins Cancer Center, a grantee of Gilead, is expanding its mobile cancer screening services in Louisiana and Mississippi. This initiative aims to increase access to early cancer detection, particularly in communities with higher mortality rates from advanced cancer diagnoses. The mobile clinics, operational since 2006, now serve 30 parishes in Louisiana and four counties in Mississippi, offering screenings for various cancers, including breast and prostate. The project is part of Gilead's Toward Health Equity Oncology Grant, which supports interventions for Black individuals impacted by breast cancer.

Gilead Sciences (NASDAQ: GILD) announced promising results from the Phase 2 TROPHY-U-01 trial of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer (mUC). Key findings include:

• 13.5 months median overall survival (OS) in platinum-ineligible patients.
• 12.8 months OS in rapidly progressing mUC post-platinum therapy.
• 10.9 months OS for patients after platinum-based chemotherapy and checkpoint inhibitors.

These results indicate potential for Trodelvy as a cornerstone treatment for challenging mUC cases. Gilead anticipates further data from the ongoing Phase 3 TROPiCS-04 study.

Gilead Sciences is committed to innovation, with plans to deliver over 10 transformative therapies by 2030 across virology, oncology, and inflammation. Recent strategic moves include the acquisition of MiroBio, which focuses on restoring immune balance, and a partnership with MacroGenics to develop bispecific antibodies for blood cancers. A new Research Center is set to be established in Foster City, featuring 175,000 square feet of lab space to enhance research capabilities. This facility aligns with Gilead's sustainable practices and is designed to foster collaboration among researchers.